tetano
Editor, Senior Moderator
Cell Rep Med
. 2022 Mar 29;3(4):100603.
doi: 10.1016/j.xcrm.2022.100603. eCollection 2022 Apr 19.
Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination
Grace Mantus[SUP] 1 2 3 [/SUP], Lindsay E Nyhoff[SUP] 1 2 3 [/SUP], Venkata-Viswanadh Edara[SUP] 1 2 3 4 [/SUP], Veronika I Zarnitsyna[SUP] 5 [/SUP], Caroline R Ciric[SUP] 1 3 [/SUP], Maria W Flowers[SUP] 1 2 3 [/SUP], Carson Norwood[SUP] 1 2 3 [/SUP], Madison Ellis[SUP] 2 3 4 [/SUP], Laila Hussaini[SUP] 1 3 [/SUP], Kelly E Manning[SUP] 2 3 4 [/SUP], Kathy Stephens[SUP] 1 3 [/SUP], Evan J Anderson[SUP] 1 3 6 [/SUP], Rafi Ahmed[SUP] 2 5 [/SUP], Mehul S Suthar[SUP] 1 2 3 4 5 [/SUP], Jens Wrammert[SUP] 1 2 3 [/SUP]
Affiliations
Abstract
The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic highlights the importance of determining the breadth and durability of humoral immunity to SARS-CoV-2 mRNA vaccination. Herein, we characterize the humoral response in 27 naive and 40 recovered vaccinees. SARS-CoV-2-specific antibody and memory B cell (MBC) responses are durable up to 6 months, although antibody half-lives are shorter for naive recipients. The magnitude of the humoral responses to vaccination strongly correlates with responses to initial SARS-CoV-2 infection. Neutralization titers are lower against SARS-CoV-2 variants in both recovered and naive vaccinees, with titers more reduced in naive recipients. While the receptor-binding domain (RBD) is the main neutralizing target of circulating antibodies, Moderna-vaccinated naives show a lesser reliance on RBDs, with >25% neutralization remaining after depletion of RBD-binding antibodies. Overall, we observe that vaccination induces higher peak titers and improves durability in recovered compared with naive vaccinees. These findings have broad implications for current vaccine strategies deployed against the SARS-CoV-2 pandemic.
Keywords: RBD; SARS-CoV-2; antibody durability; humoral response; mRNA vaccination; memory B cells.
. 2022 Mar 29;3(4):100603.
doi: 10.1016/j.xcrm.2022.100603. eCollection 2022 Apr 19.
Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination
Grace Mantus[SUP] 1 2 3 [/SUP], Lindsay E Nyhoff[SUP] 1 2 3 [/SUP], Venkata-Viswanadh Edara[SUP] 1 2 3 4 [/SUP], Veronika I Zarnitsyna[SUP] 5 [/SUP], Caroline R Ciric[SUP] 1 3 [/SUP], Maria W Flowers[SUP] 1 2 3 [/SUP], Carson Norwood[SUP] 1 2 3 [/SUP], Madison Ellis[SUP] 2 3 4 [/SUP], Laila Hussaini[SUP] 1 3 [/SUP], Kelly E Manning[SUP] 2 3 4 [/SUP], Kathy Stephens[SUP] 1 3 [/SUP], Evan J Anderson[SUP] 1 3 6 [/SUP], Rafi Ahmed[SUP] 2 5 [/SUP], Mehul S Suthar[SUP] 1 2 3 4 5 [/SUP], Jens Wrammert[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 35480625
- PMCID: PMC8960152
- DOI: 10.1016/j.xcrm.2022.100603
Abstract
The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic highlights the importance of determining the breadth and durability of humoral immunity to SARS-CoV-2 mRNA vaccination. Herein, we characterize the humoral response in 27 naive and 40 recovered vaccinees. SARS-CoV-2-specific antibody and memory B cell (MBC) responses are durable up to 6 months, although antibody half-lives are shorter for naive recipients. The magnitude of the humoral responses to vaccination strongly correlates with responses to initial SARS-CoV-2 infection. Neutralization titers are lower against SARS-CoV-2 variants in both recovered and naive vaccinees, with titers more reduced in naive recipients. While the receptor-binding domain (RBD) is the main neutralizing target of circulating antibodies, Moderna-vaccinated naives show a lesser reliance on RBDs, with >25% neutralization remaining after depletion of RBD-binding antibodies. Overall, we observe that vaccination induces higher peak titers and improves durability in recovered compared with naive vaccinees. These findings have broad implications for current vaccine strategies deployed against the SARS-CoV-2 pandemic.
Keywords: RBD; SARS-CoV-2; antibody durability; humoral response; mRNA vaccination; memory B cells.